Revelation Biosciences Confirms Common Stock & Warrant Details

Ticker: REVBW · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1810560

Revelation Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyRevelation Biosciences, Inc. (REVBW)
Form Type8-K
Filed DateJan 30, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001, $12,075.00
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, securities-details, warrants

TL;DR

**Revelation Biosciences just confirmed its common stock and warrant details in an 8-K.**

AI Summary

Revelation Biosciences, Inc. filed an 8-K on January 30, 2024, to disclose that its common stock, with a par value of $0.0001 per share, is registered on an exchange. The filing also notes the existence of redeemable warrants, each exercisable for 1/1050th of a common stock share at an exercise price of $12,075.00 per share. This matters to investors because it confirms the tradability of their common stock and provides specific details about the terms of outstanding warrants, which could impact future share dilution or capital raises.

Why It Matters

This filing confirms the basic structure of Revelation Biosciences' publicly traded securities, providing clarity on its common stock and the terms of its warrants, which is fundamental information for current and prospective investors.

Risk Assessment

Risk Level: low — This filing is purely informational, confirming existing security details, and does not introduce new financial risks or operational changes.

Analyst Insight

A smart investor would use this filing to confirm the current terms of Revelation Biosciences' common stock and warrants, integrating this foundational data into their broader analysis of the company's financial health and potential for future capital events.

Key Numbers

  • $0.0001 — Common Stock Par Value (The nominal value assigned to each share of common stock.)
  • 1/1050th — Warrant Exercise Ratio (The fraction of a common stock share each redeemable warrant is exercisable for.)
  • $12,075.00 — Warrant Exercise Price (The price at which each warrant can be exercised to obtain a fraction of a common stock share.)

Key Players & Entities

  • REVELATION BIOSCIENCES, INC. (company) — the registrant filing the 8-K
  • $0.0001 (dollar_amount) — par value per share of common stock
  • $12,075.00 (dollar_amount) — exercise price per share for redeemable warrants
  • January 30, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

  • The company's common stock will continue to be listed on an exchange. (REVELATION BIOSCIENCES, INC.) — high confidence, target: Ongoing
  • The terms of the redeemable warrants, including the exercise price and ratio, will remain as stated unless a new filing indicates a change. (REVELATION BIOSCIENCES, INC.) — high confidence, target: Ongoing

FAQ

What is the par value of Revelation Biosciences, Inc.'s common stock?

According to the filing, the common stock of Revelation Biosciences, Inc. has a par value of $0.0001 per share.

What is the exercise price for Revelation Biosciences, Inc.'s redeemable warrants?

The redeemable warrants of Revelation Biosciences, Inc. have an exercise price of $12,075.00 per share.

How many shares of common stock can one redeemable warrant be exercised for?

Each redeemable warrant is exercisable for 1/1050th of a common stock share.

When was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was January 30, 2024.

What is the Commission File Number for Revelation Biosciences, Inc.?

The Commission File Number for Revelation Biosciences, Inc. is 001-39603.

Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-30 17:21:32

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
  • $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 30, 2024, Revelation Biosciences, Inc. (the "Company") made an updated corporate presentation available to the public, the corporate presentation can be found on the Company's website. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 and in Exhibit 99.1 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation dated January 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: January 30, 2024 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.